We evaluated CDK4 rs2069502, CDK6 rs2285332, CCND1 rs9344, p16INK4a rs11515, p15INK4b rs3217986, and RB rs3092904 polymorphisms using TaqMan® SNP Assays in a cohort comprising 532 prostate cancer patients and 567 control subjects. This evidence concerns the gene CDKN2A and prostate cancer.